245 related articles for article (PubMed ID: 33383646)
1. ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models.
Yeom DH; Lee YS; Ryu I; Lee S; Sung B; Lee HB; Kim D; Ahn JH; Ha E; Choi YS; Lee SH; You WK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383646
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
[TBL] [Abstract][Full Text] [Related]
3. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models.
Zhou R; Wang S; Wen H; Wang M; Wu M
Exp Cell Res; 2019 Jul; 380(2):141-148. PubMed ID: 31034805
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis.
Lee D; Kim D; Choi YB; Kang K; Sung ES; Ahn JH; Goo J; Yeom DH; Jang HS; Moon KD; Lee SH; You WK
MAbs; 2016 Jul; 8(5):892-904. PubMed ID: 27049350
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model.
Mueller T; Freystein J; Lucas H; Schmoll HJ
Molecules; 2019 Aug; 24(16):. PubMed ID: 31394786
[TBL] [Abstract][Full Text] [Related]
6. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
[TBL] [Abstract][Full Text] [Related]
7. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
8. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.
Jimeno A; Moore KN; Gordon M; Chugh R; Diamond JR; Aljumaily R; Mendelson D; Kapoun AM; Xu L; Stagg R; Smith DC
Invest New Drugs; 2019 Jun; 37(3):461-472. PubMed ID: 30229512
[TBL] [Abstract][Full Text] [Related]
9. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
10. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Yen WC; Fischer MM; Hynes M; Wu J; Kim E; Beviglia L; Yeung VP; Song X; Kapoun AM; Lewicki J; Gurney A; Simeone DM; Hoey T
Clin Cancer Res; 2012 Oct; 18(19):5374-86. PubMed ID: 22952347
[TBL] [Abstract][Full Text] [Related]
11. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2.
Scheuer W; Thomas M; Hanke P; Sam J; Osl F; Weininger D; Baehner M; Seeber S; Kettenberger H; Schanzer J; Brinkmann U; Weidner KM; Regula J; Klein C
MAbs; 2016; 8(3):562-73. PubMed ID: 26864324
[TBL] [Abstract][Full Text] [Related]
13. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
14. Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
Djokovic D; Trindade A; Gigante J; Pinho M; Harris AL; Duarte A
BMC Cancer; 2015 Aug; 15():608. PubMed ID: 26314892
[TBL] [Abstract][Full Text] [Related]
15. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
[TBL] [Abstract][Full Text] [Related]
16. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
[TBL] [Abstract][Full Text] [Related]
17. Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Kienast Y; Klein C; Scheuer W; Raemsch R; Lorenzon E; Bernicke D; Herting F; Yu S; The HH; Martarello L; Gassner C; Stubenrauch KG; Munro K; Augustin HG; Thomas M
Clin Cancer Res; 2013 Dec; 19(24):6730-40. PubMed ID: 24097868
[TBL] [Abstract][Full Text] [Related]
18. Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition.
Yeku OO; Rao TD; Laster I; Kononenko A; Purdon TJ; Wang P; Cui Z; Liu H; Brentjens RJ; Spriggs D
Front Immunol; 2021; 12():663379. PubMed ID: 33936101
[TBL] [Abstract][Full Text] [Related]
19. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
Li Y; Hickson JA; Ambrosi DJ; Haasch DL; Foster-Duke KD; Eaton LJ; DiGiammarino EL; Panchal SC; Jiang F; Mudd SR; Zhang C; Akella SS; Gao W; Ralston SL; Naumovski L; Gu J; Morgan-Lappe SE
Mol Cancer Ther; 2018 May; 17(5):1039-1050. PubMed ID: 29592882
[TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
